RespireRx Pharmaceuticals Inc., the University of Alberta and the University of Florida Provide Update on Collaborative Resea...
April 01 2016 - 8:30AM
Marketwired
RespireRx Pharmaceuticals Inc., the University of Alberta and
the University of Florida Provide Update on Collaborative Research
Activities
Use of Ampakines as a Novel Therapy for Overcoming Central
Respiratory Depression
GLEN ROCK, NJ-(Marketwired - Apr 1, 2016) - RespireRx
Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"),
a leader in the development of medicines for respiratory disorders,
including sleep apneas and drug-induced respiratory depression, is
providing an update on the Company's collaborative research and
development programs.
Scientists at the University of Alberta in Edmonton, Alberta,
Canada and the University of Florida in Gainesville, Florida will
present their collaborative data on the use of ampakines being
developed by RespireRx as a novel therapy for overcoming central
respiratory depression at the Experimental Biology Conference being
held on April 2 - 6, 2016 in San Diego, California.
Dr. John Greer, Professor of Physiology, University of Alberta
and Chairman of the RespireRx Scientific Advisory Board, will
present a symposium paper on the use of ampakines to overcome
opioid-induced respiratory depression. Dr. Greer's presentation has
direct relevance for the potential to provide a pharmacological
solution to assist with the serious and rapidly growing problem of
overdose from the use of fentanyl and oxycodone.
Dr. David Fuller, Professor in the Department of Physical
Therapy at the University of Florida, and his research team will
present data they generated in a collaborative initiative with Dr.
Greer demonstrating that ampakines can significantly improve
respiratory function after spinal cord injury. Dr. Greer and Dr.
Fuller also demonstrated that ampakines boost the efficacy of an
emerging therapy using intermittent hypoxia that strengthens the
motor control of patients after spinal cord injury.
Dr. Greer commented, "Dr. Fuller's laboratory has made
impressive progress in demonstrating the potential for ampakine
therapy to help patients with spinal cord injury. Our strategy is
to collaborate with leading laboratories, such as the research
group at the University of Florida, to test our ideas on how
ampakines may overcome a wide range of unmet clinical needs related
to respiratory depression caused by disease, drugs and injury.
These efforts are now starting to show promising results with rapid
and exciting progress on a number of fronts."
Based on the research to be presented by Dr. Greer and a license
facilitated through TEC Edmonton on behalf of the University of
Alberta, RespireRx recently initiated a clinical trial at the Duke
University School of Medicine Clinical Research Unit to study the
use ampakines as a means of preventing opioid-induced respiratory
depression. "Supporting healthcare innovation has always been a
priority for us and we're delighted to see Dr. Greer's work
proceeding into clinical trials," said Chris Lumb, CEO of TEC
Edmonton. "Dr. Greer's research is a prime example of the world
class innovation produced at the University of Alberta. It's
exciting to see it already demonstrating tremendous potential to
improve quality of life for patients faced with respiratory
challenges."
In acknowledgement of the fruitful collaboration between the
University of Alberta, the University of Florida and RespireRx, Dr.
James S. Manuso, President and Chief Executive Officer of RespireRx
stated, "It is an honor for the RespireRx team to ally with such
accomplished and productive researchers at the Universities of
Alberta and Florida. We look forward to working with our
collaborators to develop medicines that have the potential to help
patients with a variety of diseases where breathing deficits play a
major role, including sleep apneas, respiratory despression, Pompe
disease and spinal cord injury."
Special Note Regarding Forward-Looking Statements: Certain
statements included or incorporated by reference in this news
release, including information as to the future financial or
operating performance of the Company and its drug development
programs, constitute forward-looking statements. The words
"believe," "expect," "anticipate," "contemplate," "target," "plan,"
"intend," "continue," "budget," "estimate," "may," "schedule" and
similar expressions identify forward-looking statements.
Forward-looking statements include, among other things, statements
regarding future plans, targets, estimates and assumptions.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by the
Company, are inherently subject to significant business, economic
and competitive uncertainties and contingencies. Many factors could
cause the Company's actual results to differ materially from those
expressed or implied in any forward-looking statements made by, or
on behalf of, the Company. Due to these various risks and
uncertainties, actual events may differ materially from current
expectations. Investors are cautioned that forward-looking
statements are not guarantees of future performance and,
accordingly, investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
Forward-looking statements are made as of the date of this news
release and the Company disclaims any intent or obligation to
update publicly such forward-looking statements, whether as a
result of new information, future events or results or
otherwise.
Contact Information
- RespireRx Contact: Jeff Margolis Vice-President, Treasurer and
Secretary Telephone: (917) 834-7206 E-mail:
jmargolis@respirerx.com
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024